Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs. 2013 Aug; 31(4):1023-34.

View in: PubMed

subject areas

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Cytarabine
Demography
Female
Humans
Idarubicin
Inhibitor of Apoptosis Proteins
Leukemia, Myeloid, Acute
Male
Middle Aged
Oligonucleotides
Oligonucleotides, Antisense
Recurrence
Treatment Outcome

authors with profiles

MICHAEL ANDREEFF